Showing 7471-7480 of 9753 results for "".
- ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trialhttps://practicaldermatology.com/news/iconic-lead-icotrokinra-clears-almost-half-of-psoriasis-patients-in-phase-3-trial/2471543/Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting. The
- AAD Posters Highlight Positive Data for Roflumilasthttps://practicaldermatology.com/news/AAD-Posters-Highlight-Positive-Data-Roflumilast/2471539/Arcutis Biotherapeutics, Inc., announced new data from two posters shared at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The first poster presentation details the positive efficacy, patient-reported outcomes, and tolerability for the use of once-daily
- 2-Year Data: Bimekizumab Can Eliminate Draining Tunnels in HShttps://practicaldermatology.com/news/2-Year-Data-Bimekizumab-Can-Eliminate-Draining-Tunnels-HS/2471535/Two-year data from the BE HEARD trials for bimekizumab-bkzx (BIMZELX®) in moderate-to-severe hidradenitis suppurativa (HS) continued to demonstrate sustained disease control and durable relief from key HS symptoms, including the potential to help prevent long-term structural damage caused by drai
- Treat the Whole Patient: Enhancing Care in Pediatric Alopecia Areatahttps://practicaldermatology.com/news/enhancing-care-for-pediatric-alopecia-patients/2471536/Understanding and treating pediatric alopecia areata (AA), and its impact on the emotional and social lives of children and young people, was the subject of a presentation by dermatologist Brittany Craiglow, MD, PhD, FAAD. Addr
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- JAK Inhibitors' Applications Continue to Expandhttps://practicaldermatology.com/news/JAK-Inhibitors-Applications-Continue-Expand/2471523/While JAK inhibitors have become widely popular for several common skin diseases, their potential for other indications remains vast, and Ruth Ann Vleugels, MD, MPA, MPH, FAAD, highlighted some of these in “JAK Inhibitors for Lupus, Dermatomyositis, and SAVI” at the 2025 American Academy of Derma
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog
- Closing Gaps: Takeda Enhances Diversity in Psoriasis Trialshttps://practicaldermatology.com/news/closing-gaps-takeda-enhances-diversity-in-psoriasis-trials/2471442/Takeda’s phase 3 psoriasis (PsO) clinical trials in the United States achieved success in enhancing racial and ethnic diversity among participants, according to new data from the manufacturer. Psoriasis affects over 7.5 millio
- Analysis: Nicotinamide Not Linked to Elevated MACE Riskhttps://practicaldermatology.com/news/study-nicotinamide-not-linked-to-mace-risk/2471380/Results from a new retrospective cohort study suggest nicotinamide exposure was not associated with an increased risk of major adverse cardiovascular events (MACE). The analysis included data from 13,108 patients in the Vanderb
- Cardio-Dermatology: Multidisciplinary Care Essential for Reducing Multifaceted Riskhttps://practicaldermatology.com/news/cardio-dermatology-multidisciplinary-care-essential-for-reducing-multifaceted-risk/2471287/Chronic skin conditions like psoriasis and atopic dermatitis (AD) are more than skin-deep—they carry significant risks for heart disease and require special attention, according to a compelling presentation given at Masterclasses in Dermatology 2025 in Sarasota. In her talk, Brittany Weber